title: Regulatory effects of lactoferrin and lipopolysaccharide on LFA-1 expression on human peripheral blood mononuclear cells.
abstract: The aim of this study was to investigate effects of human lactoferrin (hLF) with regard to LFA-1 expression on unstimulated and lipopolysaccharide (LPS)-activated human peripheral blood mononuclear cells (PBMC). The investigations were carried out on 30 healthy volunteers, males and females, 24-58 years old. We found that hLF, at an optimal dose of 5 microg/ml/10(6) cells in 24-hour culture, exerted regulatory effects on LFA-1 expression, depending on distribution of this molecule on cells in control cultures and on the effects of LPS. First, we revealed several patterns of LFA-1 distribution and density of this marker among studied individuals. The effects of LPS and hLF on LFA-1 expression patterns were differential. LFA-1 expression was stimulated by individual actions of LPS or hLF, additive or synergistic effects of both factors, it could be also inhibited by hLF alone or in combination with LPS. In about one third of cases no significant effects of LPS or hLF on LFA-1 expression were seen. Removal of monocytes from the PBMC population diminished LFA-1 expression in control cultures and abolished LPS- or hLF-elicited changes. The regulatory effects of hLF were also blocked by treatment of PBMC cultures with anti-tumor necrosis factor alpha (TNF-alpha) antibodies. Taken together, the data showed that hLF and LPS had immunoregulatory properties with respect to LFA-1 expression on human PBMC and that these actions were mediated by monocytes and TNF-alpha.
authors.affiliation: Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław.
authors.forename: M
authors.initials: M
authors.lastname: Zimecki
authors.forename: R
authors.initials: R
authors.lastname: Miedzybrodzki
authors.forename: J
authors.initials: J
authors.lastname: Mazurier
authors.forename: G
authors.initials: G
authors.lastname: Spik
mesh_terms: D000328:Adult; D000906:Antibodies / Q000494:pharmacology; D002478:Cells, Cultured; D015536:Down-Regulation / Q000187:drug effects; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007781:Lactoferrin / Q000494:pharmacology*; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000494:pharmacology*; D016169:Lymphocyte Function-Associated Antigen-1 / Q000096:biosynthesis*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D000906:Antibodies; D008070:Lipopolysaccharides; D016169:Lymphocyte Function-Associated Antigen-1; D014409:Tumor Necrosis Factor-alpha; D007781:Lactoferrin